The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.

<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jae Ha Lee, Ji Hoon Jang, Jin Han Park, Hang-Jea Jang, Chan Sun Park, Sunggun Lee, Seong-Ho Kim, Ji Yeon Kim, Hyun Kuk Kim
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3ba546534f9944649dc737960238aea9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ba546534f9944649dc737960238aea9
record_format	dspace
spelling	oai:doaj.org-article:3ba546534f9944649dc737960238aea92021-12-02T20:06:23ZThe role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.1932-620310.1371/journal.pone.0255365https://doaj.org/article/3ba546534f9944649dc737960238aea92021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255365https://doaj.org/toc/1932-6203<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD.<h4>Methods</h4>Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed.<h4>Results</h4>The median follow-up period was 20 months. The mean age was 68.1 years and 65.1% of the patients were men with 60.2% of patients being ever-smokers. Among ILDs, idiopathic pulmonary fibrosis was the most common disease (68.7%), followed by connective tissue disease-associated ILD (14.5%), cryptogenic organizing pneumonia (9.6%), and nonspecific interstitial pneumonia (6.0%). The serum levels of IL-6 were measured at diagnosis with ILD and sequentially at follow-up visits. During the follow-ups, 15 (18.1%) patients experienced an acute exacerbation (AE) of ILD and among them, four (26.7%) patients died. In the multivariable analysis, high levels of IL-6 (OR 1.014, 95% CI: 1.001-1.027, p = 0.036) along with lower baseline saturations of peripheral oxygen (SpO2) were independent risk factors for AE. In the receiver operating characteristic curve analysis, the area under the curve was 0.815 (p < 0.001) and the optimal cut-off value of serum IL-6 to predict AE was 25.20 pg/mL with a sensitivity of 66.7% and specificity of 80.6%. In the multivariable Cox analysis, a high level of serum IL-6 (HR 1.007, 95% CI: 1.001-1.014, p = 0.018) was only an independent risk factor for mortality in ILD patients.<h4>Conclusions</h4>In our study, a high level of serum IL-6 is a useful biomarker to predict AE and poor prognosis in patients with ILD.Jae Ha LeeJi Hoon JangJin Han ParkHang-Jea JangChan Sun ParkSunggun LeeSeong-Ho KimJi Yeon KimHyun Kuk KimPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0255365 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jae Ha Lee Ji Hoon Jang Jin Han Park Hang-Jea Jang Chan Sun Park Sunggun Lee Seong-Ho Kim Ji Yeon Kim Hyun Kuk Kim The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
description	<h4>Background</h4>Interstitial lung diseases (ILDs) are chronic, parenchymal lung diseases with a variable clinical course and a poor prognosis. Within various clinical courses, acute exacerbation (AE) is a devastating condition with significant morbidity and high mortality. The aim of this study was to investigate the role of interleukin-6 (IL-6) to predict AE and prognosis in patients with ILD.<h4>Methods</h4>Eighty-three patients who were diagnosed with ILD from 2016 to 2019 at the Haeundae Paik Hospital, Busan, South Korea, were included and their clinical data were retrospectively analyzed.<h4>Results</h4>The median follow-up period was 20 months. The mean age was 68.1 years and 65.1% of the patients were men with 60.2% of patients being ever-smokers. Among ILDs, idiopathic pulmonary fibrosis was the most common disease (68.7%), followed by connective tissue disease-associated ILD (14.5%), cryptogenic organizing pneumonia (9.6%), and nonspecific interstitial pneumonia (6.0%). The serum levels of IL-6 were measured at diagnosis with ILD and sequentially at follow-up visits. During the follow-ups, 15 (18.1%) patients experienced an acute exacerbation (AE) of ILD and among them, four (26.7%) patients died. In the multivariable analysis, high levels of IL-6 (OR 1.014, 95% CI: 1.001-1.027, p = 0.036) along with lower baseline saturations of peripheral oxygen (SpO2) were independent risk factors for AE. In the receiver operating characteristic curve analysis, the area under the curve was 0.815 (p < 0.001) and the optimal cut-off value of serum IL-6 to predict AE was 25.20 pg/mL with a sensitivity of 66.7% and specificity of 80.6%. In the multivariable Cox analysis, a high level of serum IL-6 (HR 1.007, 95% CI: 1.001-1.014, p = 0.018) was only an independent risk factor for mortality in ILD patients.<h4>Conclusions</h4>In our study, a high level of serum IL-6 is a useful biomarker to predict AE and poor prognosis in patients with ILD.
format	article
author	Jae Ha Lee Ji Hoon Jang Jin Han Park Hang-Jea Jang Chan Sun Park Sunggun Lee Seong-Ho Kim Ji Yeon Kim Hyun Kuk Kim
author_facet	Jae Ha Lee Ji Hoon Jang Jin Han Park Hang-Jea Jang Chan Sun Park Sunggun Lee Seong-Ho Kim Ji Yeon Kim Hyun Kuk Kim
author_sort	Jae Ha Lee
title	The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_short	The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_full	The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_fullStr	The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_full_unstemmed	The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
title_sort	role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/3ba546534f9944649dc737960238aea9
work_keys_str_mv	AT jaehalee theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jihoonjang theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jinhanpark theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hangjeajang theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT chansunpark theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT sunggunlee theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT seonghokim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jiyeonkim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hyunkukkim theroleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jaehalee roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jihoonjang roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jinhanpark roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hangjeajang roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT chansunpark roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT sunggunlee roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT seonghokim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT jiyeonkim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases AT hyunkukkim roleofinterleukin6asaprognosticbiomarkerforpredictingacuteexacerbationininterstitiallungdiseases
_version_	1718375355039875072

The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases.

Ejemplares similares